Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$2.88MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Adam R. Craig
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 45
- Beta
- 0.35
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -1.98
Financials
Revenue
$2.88M-4.0%Net Income
$-20.20MEBITDA
$-17.67MFree Cash Flow
$-20.19MEPS (diluted)
$-0.16Shares Outstanding (diluted)
126.52M+31764.6%Operating Expenses
$22.36MCash & Debt
$187.70MReturn of Capital
$0.00Revenue by Segment (annual)
$35.11MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $35.11M | $-79.20M | $-1.87 |
| 2024 | $2.56M | $-37.45M | $-5.59 |
| 2023 | $0.00 | $-101.17M | $-17.07 |
| 2022 | $0.00 | $-93.87M | $-45.60 |
| 2021 | $0.00 | $-88.70M | $-119.58 |
| 2020 | $3.00M | $-62.13M | $-92.84 |
| 2019 | $0.00 | $-52.81M | $-138.94 |
| 2018 | $0.00 | $-33.28M | $-14238.00 |
| 2017 | $0.00 | $-33.88M | $-17767.00 |
| 2016 | $0.00 | $-22.98M | $-1737.74 |
| 2015 | $0.00 | $-13.22M | $-1266.46 |
Valuation
XFORhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (9)
- Newsglobenewswire.com·19d ago·Neutral
X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026 BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in several upcoming investment conferences in November 2026:
View source ↗ - Newsseekingalpha.com·23d ago·Positive
X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day Transcript X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day Transcript
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day - Base Case U.S. Market Opportunity Estimated at 15,000 Patients, With Potential to Expand to Approximately 30,000 Patients -
View source ↗ - Newsglobenewswire.com·44d ago·Neutral
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual Investor Day on Thursday, October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
… Completion of Enrollment in Phase 3 4WARD trial by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that it has entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures LLC (“K2HV”), an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and…
View source ↗ - Newszacks.com·59d ago·Neutral
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround X4 Pharmaceuticals (XFOR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newszacks.com·72d ago·Neutral
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner X4 Pharmaceuticals (XFOR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
View source ↗ - Newsglobenewswire.com·74d ago·Neutral
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET.
View source ↗ - Newszacks.com·103d ago·Positive
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗
Earnings
Tue, Mar 16(in 4 months)
Consensus estimate $-0.22 per share
Typical surprise +23.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.16 vs $-0.17beat
- Fri, Aug 7$-0.13 vs $-0.18beat
- Wed, May 6$-0.16 vs $-0.20beat
- Tue, Mar 17$-0.22 vs $-0.36beat
- Wed, Nov 5$-0.69 vs $-0.79beat
- Fri, Aug 8$-3.47 vs $-4.53beat
Estimates and results for XFOR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by XFOR officers and directors.
- Bought
- $284k
- Sold
- $1.6m
5 trades
32 trades
- Craig Adam Rbought
- Kirske Davidsold
- Volpone Johnsold
- Craig Adam Rsold
- Kirske Davidsold
- Kirske Davidsold
- Craig Adam Rbought
- Baldry Markbought
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in XFOR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
